| [1] | Uson, J., Rodriguez-García, S. C., Castellanos-Moreira, R., et al. (2021). EULAR recommendations for intra-articular therapies. Ann Rheum Dis, 80:1299−1305. DOI:10.1136/annrheumdis-2021-220266 |
| [2] | Wen, J., Li, H., Dai, H., Hua, S., et al. (2023). Intra-articular nanoparticles based therapies for osteoarthritis and rheumatoid arthritis management. Mater Today Bio, 19:100597. DOI:10.1016/j.mtbio.2023.100597 |
| [3] | Chen, J., Deng, M., Wang, J., et al. (2025). Recent advances in injectable hydrogels for osteoarthritis treatments. Front Bioeng Biotechnol, 13:1644222. DOI:10.3389/fbioe.2025.1644222 |
| [4] | Welsh, J. A., Goberdhan, D. C. I., O'Driscoll, L., et al. (2024). Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles, 13:e12404. DOI:10.1002/jev2.12404 |
| [5] | DeJulius, C. R., Walton, B. L., Colazo, J. M., et al. (2024). Engineering approaches for RNA-based and cell-based osteoarthritis therapies. Nat Rev Rheumatol, 20:81−100. DOI:10.1038/s41584-023-01067-4 |
| Liu J., Wang Z., Shen H., et al. (2026). Clinical pharmacy management of emerging intra-articular drug delivery systems for knee osteoarthritis: A practical guideline. The Innovation Drug Discovery 1:100025. https://doi.org/10.59717/j.xinn-drugdisc.2026.100025 |
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
Pharmaceutical management framework for emerging intra-articular drug delivery systems in early- to mid-stage knee osteoarthritis